IL-6/IL-8 expression inhibited by PI3K inhibitor LY-294002

Addition of PI3K inhibitor LY-294002 to S.mutans stimulated human odontoblast-like cells resulted in the reduced gene expression of IL-6 and IL-8

Schering Plough initiate Phase I trial of CDK inhibitor SCH-727965 in breast cancer

Schering Plough have initiated a phase I trial of CDK 1/2/9  inhibitor SCH 727965 in patients with advanced breast and lung cancers

EntreMed partner with JSB for Aurora Kinase Program

EntreMed have partnered with JSB-Partners to enhance business development and partnering activities for its lead Aurora A/angiogenesis kinase inhibitor, ENMD-2076.

Cytopia to present on JAK2 program at ACS meeting

Cytopia have announced that it will be presenting data on its JAK2 program at the Philadelphia ACS meeting.